Crizotinib

Back to search

Molecule Structure

Scientific Name

Crizotinib

Description of the Drug

Crizotinib is a receptor tyrosine kinase inhibitor used to treat metastatic non-small cell lung cancer (NSCLC) where the tumors have been confirmed to be anaplastic lymphoma kinase (ALK), or ROS1-positive.

Source: DrugBank Online – DrugBank.com. Retrieved 2023-02-07 from
http://www.drugbank.ca/drugs/DB08865

Brand Name(s)

Xalkori

Company Owner(s)

Pf Prism Cv

Mechanism(s) Of Action

Target Name Target Type Action Type Target ChEMBL ID
Hepatocyte growth factor receptor SINGLE PROTEIN INHIBITOR CHEMBL3717
ALK tyrosine kinase receptor SINGLE PROTEIN INHIBITOR CHEMBL4247
NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) CHIMERIC PROTEIN INHIBITOR CHEMBL2111387
EML4-ALK CHIMERIC PROTEIN INHIBITOR CHEMBL3883330

Unichem Links

SureChEMBL SCHEMBL93829
PharmGKB PA165946122
DrugBank DB08865
PubChem: Thomson Pharma 16729581
PubChem 11626560
LINCS LSM-1027
Nikkaji J2.735.431I
PDBe VGH
BindingDB 50306682
DrugCentral 4187
Brenda 213556 62615
Guide to Pharmacology 4903
GSRS f6f83e6a-308c-4d00-9bc9-229e373e8c55
rxnorm XALKORI CRIZOTINIB
PubChem: Drugs of the Future 125299329
ChEBI 64310
ZINC ZINC000035902489